Written from the perspective of an Australian medical practitioner. Educational information only — always discuss your individual situation with your GP or oncologist.
If you or someone you love has been diagnosed with breast cancer — yes, even male breast cancer — the word tamoxifen may be one of the most important words you will ever hear. Around 20,000 Australian women and approximately 170 Australian men are diagnosed with breast cancer every year. Roughly 70–80% of these cancers are hormone receptor positive, meaning they grow in response to oestrogen. Tamoxifen is not a new, experimental drug. It has been a cornerstone of breast cancer treatment for more than 40 years and remains one of the most life-saving, cost-effective oral cancer medicines available on the Australian Pharmaceutical Benefits Scheme (PBS).
As a doctor, I see many patients over 30 who are scared, overwhelmed, and confused by the side-effect information they find online. My goal here is to give you a clear, balanced, Australian perspective. The truth is: tamoxifen saves lives, and for most people the benefits far outweigh the manageable risks.
Tamoxifen is a selective oestrogen receptor modulator (SERM). In breast tissue, it blocks oestrogen from attaching to cancer cells, starving them of the signal they need to grow. In other tissues, such as bone and the uterus, it can have weak oestrogen-like effects — which is why monitoring matters.
In Australia, tamoxifen is TGA-approved and PBS-listed for:
Large international meta-analyses show that five years of tamoxifen can reduce the 15-year risk of breast cancer death by about one-third in oestrogen receptor-positive disease. That is a powerful reason to keep taking it even when side effects feel difficult.
Many people feel anxious about blood clots, pulmonary embolism, vaginal bleeding, pelvic examinations, and whether the tablet contains lactose. Let me address these pain points directly, because knowledge is the best medicine for fear.
| Topic | What you need to know | Australian action plan |
|---|---|---|
| Is tamoxifen used for male breast cancer? | Yes. Tamoxifen is the standard adjuvant hormone therapy for hormone receptor-positive male breast cancer in Australia. Men tolerate it well and it significantly reduces recurrence. | Male patients should be managed by a multidisciplinary team including a medical oncologist. Regular follow-up and breast imaging are still required. |
| Can tamoxifen cause pulmonary embolism? | Yes, tamoxifen slightly increases the risk of blood clots, including deep vein thrombosis and pulmonary embolism. The absolute risk is low — about 2–3 extra clot events per 1,000 people per year. Risk is higher if you smoke, are obese, have a history of clots, or are immobile. | Before prescribing, your doctor should assess your clotting risk. Know the warning signs: sudden shortness of breath, chest pain, calf swelling or pain. Seek emergency care if these occur. |
| Do I need an annual pelvic exam on tamoxifen? | Yes, if you have a uterus. Tamoxifen can stimulate the endometrium, causing thickening, polyps, or rarely endometrial cancer. Annual pelvic examination allows early detection of changes. If you have had a hysterectomy, this specific monitoring is not needed. | Book an annual gynaecological check-up with your GP or gynaecologist. Report any abnormal bleeding immediately — do not wait for the annual visit. |
| Australia’s surveillance protocol on tamoxifen | Cancer Australia and oncology follow-up guidelines recommend regular review with your oncology team, annual breast imaging and clinical breast examination. For tamoxifen users with a uterus, annual gynaecological review is advised. Routine transvaginal ultrasound is not required unless symptoms develop. | Keep your follow-up appointments. In the first few years after diagnosis, visits may be every 3–6 months, then less often. Ask your oncologist for a written surveillance plan. |
| What is the TGA adverse event reporting scheme? | The Therapeutic Goods Administration (TGA) runs Australia’s national system for reporting suspected side effects of medicines. Reporting helps monitor tamoxifen’s safety for all Australians. | You or your doctor can report side effects online at the TGA website or by calling 1800 020 653. Ask your doctor about the “Blue Card” reporting system. |
| How to reduce the risk of blood clots on tamoxifen | You can lower your clot risk with simple lifestyle steps: stay active, avoid smoking, maintain a healthy weight, stay hydrated, and avoid long periods of immobility. During long-haul flights or car trips, move regularly and consider compression stockings. | If you are planning surgery or a long period of bed rest, tell your doctor — tamoxifen may be temporarily paused. Never start oestrogen-containing hormone therapy or combined oral contraceptives without medical advice. |
| Does tamoxifen contain lactose? | Many tamoxifen tablet brands available in Australia contain lactose monohydrate as an inactive filler. The amount is very small and usually tolerated even by people with lactose intolerance. Severe lactose allergy is different and requires attention. | Check the Consumer Medicines Information (CMI) for your specific brand. If you need a lactose-free option, talk to your pharmacist or doctor — alternatives or compounding may be possible. Do not stop tamoxifen without medical advice. |
| What to do if vaginal bleeding occurs on tamoxifen | Any postmenopausal bleeding or unusual vaginal bleeding while taking tamoxifen must be reported promptly to your GP or oncologist. Most cases are benign, such as atrophic vaginitis or polyps, but investigation is essential. | Contact your doctor immediately. You will likely be referred for a pelvic examination, vaginal ultrasound, and possibly endometrial biopsy. Early reporting leads to simple, effective management. |
Let me be direct with you. The fear of side effects leads some Australian patients to stop tamoxifen early — and that decision can cost lives. Yes, tamoxifen has risks: blood clots, endometrial changes, hot flushes, vaginal discharge, and mood changes. But these risks are monitorable, manageable, and often reversible. In contrast, the risk of breast cancer recurrence is not always manageable once it happens.
As a doctor, my job is not to pretend tamoxifen is perfectly safe. My job is to help you weigh the risk of the medicine against the risk of the disease. For the vast majority of hormone receptor-positive breast cancer patients over 30, tamoxifen offers a survival advantage that far outweighs the low absolute risk of serious side effects.
If you are over 30 and you have been prescribed tamoxifen — or you think you might benefit from it — do not let fear stop you from taking action. Here is exactly what I recommend:
Tamoxifen is not just a tablet — it is a life-saving tool. With the right monitoring, Australian patients over 30 can take it with confidence. Talk to your doctor today, and take the next step towards protecting your future.
Disclaimer: This article is for educational and informational purposes only and does not constitute individual medical advice. Tamoxifen is a prescription-only medicine in Australia. Always consult a qualified medical practitioner before starting, stopping, or changing any medication. If you experience chest pain, sudden breathlessness, or heavy vaginal bleeding, seek emergency medical care immediately.